Mindbloom Controversy: The Lawsuits and Safety Record

• Mindbloom is a legitimate company. Mindbloom, Inc. is a venture-backed Delaware corporation founded in 2018 by Dylan Beynon. It is based in Florida as of 2026, has raised about $45 million, and is not named in any FDA, DEA, FTC, state attorney general or medical board action.
• One wrongful-death lawsuit is pending. Phillip Ward’s family sued Mindbloom in North Carolina on October 21, 2025, alleging that the 27-year-old died of ketamine toxicity after Mindbloom continued shipping medication while he missed mandatory consults. These are allegations, and Mindbloom denies them.
• Mindbloom is also a plaintiff. It sued the Wall Street Journal in June 2025 over a 2024 headline that placed its name next to Matthew Perry’s overdose. Perry was never a Mindbloom client. The Journal stands by the article.

Mindbloom offers at-home ketamine therapy programs starting at $1,290. Licensed psychiatric clinicians prescribe the medication after a video consult. The company faces a pending wrongful-death lawsuit filed in October 2025. A September 2024 congressional letter also named Mindbloom as an example of a telehealth service that mails ketamine, and its privacy policy says it shares data with Meta and Google. No FDA, DEA, FTC, state attorney general or medical board has taken action against Mindbloom.

ChoosingTherapy.com may earn a commission from the companies whose services are linked on this page.

What Mindbloom is and how it operates

Mindbloom, Inc. is privately held and venture-backed. PitchBook lists the company as founded in 2018, with about 200 employees and 16 investors.¹ Founder and CEO Dylan Beynon previously co-founded a legal-tech company. Mindbloom’s story page says he started the company after receiving ketamine treatment in 2018, following the overdose deaths of his mother and sister.² Named investors include Kleiner Perkins, 8VC and Founders Fund. PitchBook puts total funding at $44.9 million.³

Mindbloom opened a clinic in Manhattan in March 2020, then went fully virtual within months. Its terms now list an Orlando, Florida address, and the Ward complaint identifies Florida as its principal place of business.⁴ Mindbloom explains its structure in a note on every page: Mindbloom, Inc. provides a platform for affiliated psychiatric medical practices that are independently owned and operated. The company that receives a client’s payment is legally separate from Mindbloom Medical Group, P.C., whose clinicians prescribe.

Mindbloom’s reported treatment totals vary by page. A June 2025 court filing said the company had provided more than 695,000 treatments to nearly 60,000 patients in 35 states. On September 6, 2026, its safety page listed more than 800,000 treatments.⁵ Medical director Leonardo Vando, MD, is a board-certified psychiatrist and addiction psychiatrist. Mindbloom says it reports prescriptions to state monitoring databases.

The Mindbloom lawsuits

Ward v. Mindbloom: pending wrongful-death lawsuit

John Ward, administrator of the estate of Phillip Ward, filed the case in Pitt County Superior Court, North Carolina, on October 21, 2025. The defendants are Mindbloom, Inc., Enovex Pharmacy, LLC, physician assistant Elliot Skwerer and supervising physician Ijaz Rasul, MD.⁶

The complaint says Phillip Ward signed up in March 2023 with a history of depression, hypertension, tachycardia and substance abuse. He was moving off twice-weekly Spravato treatment in Florida. A Mindbloom clinician wrote that Ward would need a therapist before approval and required a letter from his Spravato provider. The suit alleges the defendants never confirmed that either condition had been met. It also says Ward missed video consults on June 28 and October 18, 2023. He was charged a $150 no-show fee but continued receiving medication. Ward was found dead on October 29, 2023. The complaint lists the cause of death as ketamine toxicity in the setting of hypertension, with a blood level of 9.3 mg/L. It says the blood pressure cuff in his Bloombox was unused and still in its original packaging, and that no clinician had asked for readings.⁶

The complaint brings five counts: negligence, negligent design, failure to warn, gross negligence with punitive damages, and unfair trade practices. These are allegations, and none has been tested in court.

Beynon responded on October 24, 2025. He said the facts would show that Mindbloom provides the highest quality clinical care, backed by what he described as the largest peer-reviewed clinical studies in the history of ketamine therapy and results from hundreds of thousands of treatments. He also said the care Ward received was no different from Mindbloom’s usual care.⁷ As of September 6, 2026, no answer, ruling, settlement or dismissal has been reported. A lawsuit tracker lists the case as active.

Mindbloom v. Dow Jones: pending defamation lawsuit

Mindbloom sued the Wall Street Journal’s publisher in Delaware Superior Court on June 2, 2025. The complaint challenges the August 16, 2024 headline, “People Are Injecting Ketamine at Home: Matthew Perry overdosed on anesthetic that Mindbloom is sending by mail.”⁸ Paragraph 4 states that Perry was never a Mindbloom client and never received medication from the company. Mindbloom seeks $4 million in lost profits, $35 million in lost enterprise value and $350,000 in expenses, plus punitive damages. Its own press framing puts the total at $88 million.

On June 5, 2025, a Journal spokesperson said the paper would mount a robust legal defense and called Mindbloom’s allegations feeble and unsupported.⁹ No ruling has been reported as of September 6, 2026.

Class actions

No class action against Mindbloom was found. Its terms of use, updated September 4, 2026, require individual arbitration and say client claims cannot be brought as a class action.¹⁰ Mindbloom’s website is named in an April 2025 class action against ad-tech firm PubMatic, but Mindbloom is not a defendant. The complaint alleges that a tracking pixel on mindbloom.com let advertisers infer that a visitor was seeking ketamine therapy.¹¹

Matthew Perry and Mindbloom

Matthew Perry died in October 2023 from the acute effects of ketamine. Five people, including two doctors and a dealer, were charged in connection with his death, and the dealer agreed to plead guilty. The body of the Wall Street Journal’s 2024 article says Perry began buying ketamine illicitly after doctors refused to increase his dose.¹² No outlet has reported that Mindbloom supplied him.

Mindbloom’s name appeared alongside Perry’s overdose in the headline now at issue in its lawsuit. It also appeared in a September 30, 2024 letter from Rep. Raja Krishnamoorthi to the White House drug policy office. The letter cited Perry’s death and named Mindbloom as an example of a telehealth service. It described services that let patients complete a brief questionnaire, meet a practitioner once and receive ketamine by mail.¹³ The letter did not say Mindbloom supplied Perry.

Regulators: FDA, DEA and Congress

Ketamine is not FDA-approved for any psychiatric use. In October 2023, the FDA issued an alert about compounded ketamine. It warned that at-home administration adds risk because no health care provider is onsite to monitor serious adverse outcomes from sedation and dissociation.¹⁴ Mindbloom includes that warning on its informed-consent page.

In July 2026, the FDA sent warning letters to 14 online ketamine sellers. Mindbloom was not among them.¹⁵ The Wall Street Journal reported on July 16, 2026, that federal officials had opened investigations into online ketamine sellers. The article is paywalled, and the secondary coverage we could read named no company.¹⁶

The DEA rule that allows Mindbloom’s prescribing is temporary. It lets clinicians prescribe a Schedule III drug after a video visit. The fourth extension runs through December 31, 2026, and a final rule is pending.¹⁷ In May 2023, the DEA suspended the registration of a South Carolina tele-ketamine prescriber for prescribing without adequate examinations.¹⁸ That case did not involve Mindbloom.

What clinicians and journalists have said about Mindbloom

Vice reported in November 2021 that Mindbloom ads promised five years of therapy in just a few sessions. Yale’s Gerard Sanacora told Vice that anyone claiming the treatment was totally safe had not really provided these treatments to people.¹⁹ In October 2022, Psychiatric Times’ editor in chief called at-home virtual ketamine a dangerous model. The same article criticized a 2022 study of Mindbloom clients because it had no placebo control group.²⁰

The Wall Street Journal reported in August 2024 that Mindbloom had added injectable doses in February 2024. Customers receive a blood pressure cuff with the injection supplies, but the person monitoring them needs no training. Better U’s medical director said his company did not consider that safe at all. Mindbloom’s chief strategy officer said the company had received no reports of risky blood pressure events.¹² In February 2025, Psychedelic Alpha said the injectable program had caused significant controversy in the psychedelics community. It also reported that Mindbloom dismissed the backlash as industry-driven opposition.²¹

A March 2026 STAT opinion piece analyzed six months of online patient reports and found at-home prescriptions ranging from 50 mg to 800 mg.²² The Journal published a front-page investigation on March 16, 2026, centered on the death of a Better U patient.²³ Time covered the rise of telehealth pill mills in August 2026.²⁴ The STAT piece names Mindbloom in connection with the Ward suit. Both 2026 Journal articles are paywalled, so whether they name Mindbloom is unknown.

How Mindbloom says its safety protocol works

Mindbloom is not an emergency service. Its informed consent says practice providers cannot connect clients directly to emergency services. The footer on every page tells anyone in a life-threatening situation not to use the site and to call, text or chat 988 or 1-800-273-TALK (8255) for immediate help.²⁵

Every dosing session requires a Peer Treatment Monitor, who can be a partner, family member or close friend age 18 or older. The monitor must join the prep call, stay with the client during dosing, check in every 15 minutes and call 911 in a medical emergency.²⁶ Mindbloom does not require monitor training. Clients without a monitor are told they can hire one through caregiving platforms such as Care.com.

Clients receive a blood pressure monitor and are told not to proceed if their blood pressure is above 150/100 or their heart rate is above 100 beats per minute.²⁵ The site does not say whether clients must submit those readings to a clinician. A text support line operates from 10 am to 10 pm. Mindbloom publishes no 24-hour clinical line, grievance process or clinician-reporting procedure.

Mindbloom describes its prescribers as psychiatrists, psychiatric nurse practitioners board-certified in psychiatry, or physician assistants specialized in psychiatry. Each prescriber is licensed in the client’s state. Mindbloom does not explain on its site or in its help center how it verifies those licenses. A new client receives two video consults in a six-session program. Guides run coaching sessions and group circles, but they are not clinicians. A 2022 study of Mindbloom clients says guides are not licensed professionals and do not provide psychotherapy.²⁰

Mindbloom privacy practices

Mindbloom’s privacy policy, updated September 4, 2026, says neither Mindbloom nor its medical groups is a covered entity under HIPAA.²⁷ It names Meta, Google Analytics, Google Ads, Hotjar, Impact, Microsoft Bing Ads and X as data partners. The California section says the company sells and/or shares personal information, as the CCPA defines those terms, because it uses cross-context behavioral advertising.

The help center answers “no” when asked whether Mindbloom shares client information.²⁸ Both statements were live on September 6, 2026. No data breach naming Mindbloom was found.

What Mindbloom has changed

Mindbloom launched injectables in February 2024 and has continued marketing them. Two former guides say the company restructured the guide role in late 2023 and moved support tasks to overseas staff and AI tools. Mindbloom added an AI-tools disclosure when it updated its privacy policy and terms on September 4, 2026. It also raised prices between November 2025 and January 2026.

Mindbloom has not announced a protocol change tied to the Ward lawsuit. Its site still has no published requirement to submit blood pressure readings, no 24-hour clinical line, no grievance process and no monitor training.

What clients and former guides say

Mindbloom’s Trustpilot page had 808 reviews on September 6, 2026, with an average rating of 3.9 out of 5. About two thirds were five-star reviews, and roughly one in seven was one-star.²⁹ Positive reviews tend to praise the medicine and clinicians. A September 2026 reviewer called ketamine life-changing. An August 2026 reviewer praised the trusted-peer monitoring, integration support and check-ins, but said the only concern was how frustrating it could be to reach customer support through the app.

The one-star reviews focus on operations. A March 2026 reviewer said Mindbloom had charged $430, but the medication still had not arrived 29 days later. A September 2025 reviewer said the company shipped ketamine to the wrong address three times. The BBB has logged 60 complaints against Mindbloom since opening its file in April 2022, with one complaint still unresolved. It gives Mindbloom a B+ grade and has not accredited the company.³⁰

Recurring complaints include gaps between doses, a clinician speaking to a client as if the client were an addict, and a disputed $150 no-show fee.³¹ Other users report the opposite experience and credit Mindbloom with meaningful improvement over several rounds of treatment.

Two former guides said Mindbloom restructured the guide role in late 2023. They said most guide-specific tasks moved to overseas staff and that AI tools stood in for guides without clients being told.³² One said guide ratings were tied to client repurchase rates and that some states went without nurse practitioner support for weeks.³³ Both are single-source accounts. Mindbloom disputes that characterization and says most guides have a positive experience. One of those former guides also said the client experience compares well with other options in the psychedelic therapy space.

Who Mindbloom may and may not fit

Mindbloom may fit an adult with depression or anxiety who can pay $1,290 up front. The client also needs stable blood pressure, no history of psychosis and a trusted adult at home for every session. Five-star reviews tend to praise the treatment itself, while complaints focus on shipping, support and billing. Read our Mindbloom review for the refund terms before buying.

Mindbloom does not fit anyone with hypertension, a substance use history, or a current benzodiazepine prescription without a doctor’s sign-off. Hypertension and a substance use history are among the allegations in the Ward case. The Better U lawsuit alleges that a client was prescribed ketamine while taking prescribed Xanax. For how Mindbloom compares with a lower-dose daily program, see our Joyous vs Mindbloom comparison.³⁴

Mindbloom also does not fit anyone who cannot arrange a monitor or needs a clinician available at 2 am. Spravato is FDA-approved and administered in a monitored clinic. It is an option for people with treatment-resistant depression and insurance. Most plans cover it, and we do not earn from Spravato. Talkiatry is an in-network telepsychiatry service. Start there if you would rather have psychiatric care billed to insurance than pay a program price up front.

If you are in crisis, call or text 988, the Suicide and Crisis Lifeline, or go to the nearest emergency room. Mindbloom cannot connect you to emergency services.

Mindbloom’s programs start at $1,290, and the full price is refunded if the clinician decides at the eligibility consult that you are not a medical fit.